NCT03269526View on ClinicalTrials.gov

BATs Treatment for Pancreatic Cancer, Phase Ib/II

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 28, 2017

Primary Completion Date

June 30, 2025

Study Completion Date

June 1, 2025

Conditions
Locally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic Adenocarcinoma
Interventions
DRUG

EGFR BATs after standard of care chemo

Subjects will receive one dose of standard of care chemotherapy prior to twice weekly or weekly infusions of EGFR BATs for 4 weeks.

Trial Locations (1)

22903

University of Virginia, Charlottesville

All Listed Sponsors
lead

University of Virginia

OTHER

NCT03269526 - BATs Treatment for Pancreatic Cancer, Phase Ib/II | Biotech Hunter | Biotech Hunter